TP53 and bladder transitional cell carcinoma: Some traditional clinical traits (e.g., age, gender, AJCC stage, and smoking) and emerging molecular features (e.g., mutation status of TP53 and RB1) displayed dramatic significance in the prognostic evaluation and clinical management of BLCA, for instance, compared with male, female with BLCA exhibit a worse prognosis and higher risk of death [37].